Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings in Brief: SurVivaLink

This article was originally published in The Gray Sheet

Executive Summary

SurVivaLink: Automated external defibrillator firm completes $11.2 mil. private placement of Series A preferred stock. Proceeds will go toward "aggressive global marketing," according to a June 17 release. Lead investors in the placement are Fidelity Ventures Limited and Fidelity Investors, L.P. Other institutional investors include CIBC Wood Gundy Ventures, The Spray Venture Fund, L.P., Wellmark, Inc., and Minnesota Management Partners I Limited. Wessels, Arnold & Henderson served as placement agent for the offering. SurVivaLink canceled plans to go public via an initial offering of 3 mil. shares last year due to poor market conditions, the firm explains ("The Gray Sheet" June 24, 1996, p. 13)...

You may also be interested in...

What Lies Ahead: COVID-19 Vaccination Challenges

The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.

P&G: Sales Growth Strongest When Rising Tide Floats All Competitors Across All Categories

P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.

COVID-19 Vaccine 'Brexit Bonus' A Myth

The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts